AstraZeneca (AZN) Receives “Buy” Rating from Shore Capital

Share on StockTwits

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reiterated by stock analysts at Shore Capital in a research report issued to clients and investors on Thursday.

Several other research analysts also recently commented on AZN. Liberum Capital reissued a “hold” rating on shares of AstraZeneca in a report on Tuesday, October 23rd. Credit Suisse Group set a GBX 6,350 ($82.97) price objective on shares of AstraZeneca and gave the company a “buy” rating in a report on Friday, December 7th. Bryan, Garnier & Co downgraded shares of AstraZeneca to a “neutral” rating in a report on Thursday, November 8th. Barclays reissued an “overweight” rating and set a GBX 6,800 ($88.85) price objective on shares of AstraZeneca in a report on Monday, November 19th. Finally, JPMorgan Chase & Co. reissued an “overweight” rating on shares of AstraZeneca in a report on Monday, November 19th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have given a buy rating to the stock. AstraZeneca has a consensus rating of “Buy” and a consensus target price of GBX 6,243.45 ($81.58).

AZN opened at GBX 6,012 ($78.56) on Thursday. AstraZeneca has a 52 week low of GBX 4,260 ($55.66) and a 52 week high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Featured Article: What are Closed-End Mutual Funds?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply